Phase I trial of divarasib show positive results for patients with Kras-mutated solid tumours

Press/Media: Research


Divarasib is a  KRAS G12C inhibitor. Phase 1 trial NCT04449874  showed responses in patients with solid tumours. Research published in New England Journal of Medicine. 

Period24 Aug 2023 → 5 Sept 2023

Media coverage


Media coverage